A 4-week Dose-Ranging, Dose-Interval, Efficacy, Safety and Tolerability Study of GSK961081 in Subjects With Chronic Obstructive Pulmonary Disease (COPD)

GSK Investigational Site, Durban

GSK Investigational Site, Panorama

GSK Investigational Site, Tygerberg

GSK Investigational Site, Bellville

GSK Investigational Site, Mowbray

GSK Investigational Site, Gatesville

GSK Investigational Site, Tallinn

GSK Investigational Site, Berlin

GSK Investigational Site, Berlin

GSK Investigational Site, Berlin

GSK Investigational Site, Tallinn

GSK Investigational Site, Tallinn

GSK Investigational Site, Vinnytsia

GSK Investigational Site, Lübeck

GSK Investigational Site, Dnipropetrovsk

GSK Investigational Site, Tartu

GSK Investigational Site, Frankfurt am Main

GSK Investigational Site, Kharkiv

GSK Investigational Site, Gelnhausen

GSK Investigational Site, Ivano-Frankivsk

GSK Investigational Site, Simferopol

GSK Investigational Site, Moscow

GSK Investigational Site, Saint Petersburg

GSK Investigational Site, Timișoara

GSK Investigational Site, Yekaterinburg

GSK Investigational Site, Tomsk

GSK Investigational Site, Iași

GSK Investigational Site, Dresden

GSK Investigational Site, Almelo

GSK Investigational Site, Breda

GSK Investigational Site, Eindhoven

GSK Investigational Site, Hoorn

GSK Investigational Site, Veldhoven

GSK Investigational Site, Zutphen

GSK Investigational Site, Bucharest

GSK Investigational Site, Bucharest

GSK Investigational Site, Moscow

GSK Investigational Site, Bratislava

GSK Investigational Site, Košice

GSK Investigational Site, Nitra

GSK Investigational Site, Nové Zámky

GSK Investigational Site, Zvolen

GSK Investigational Site, Boden

GSK Investigational Site, Gothenburg

GSK Investigational Site, Lund

GSK Investigational Site, Stockholm

GSK Investigational Site, Kiev

GSK Investigational Site, Kyiv

GSK Investigational Site, Kyiv